Growth hormone secretagogues (GHRH analogs and ghrelin receptor agonists)
Growth hormone secretagogues prompt the pituitary gland to release the body's own growth hormone, either by copying growth hormone-releasing hormone or by acting on the ghrelin receptor. Tesamorelin is approved to reduce excess belly fat in adults with HIV, while CJC-1295 and ipamorelin are sold without approval for muscle, fat loss, and anti-aging claims. Injection-site reactions, joint and muscle aches, fluid retention, tingling hands, and higher blood sugar are the main side effects. Because they raise growth hormone and IGF-1, they are avoided in people with active cancer and are watched closely in people with diabetes.